Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

U.S. Fecal Occult Testing Market by PRODUCT (GUAIAC FECAL OCCULT BLOOD (FOB) STOOL TEST, IMMUNO-FECAL OCCULT BLOOD (FOB) AGGLUTINATION TEST, LATERAL FLOW IMMUNO-FECAL OCCULT BLOOD (FOB) TEST, IMMUNO-FECAL OCCULT BLOOD (FOB) ELISA TEST) and by END USER (HAND-HANDLED FECAL OCCULT TESTING, TROLLEY MOUNTED FECAL OCCULT TESTING, HEADBAND FECAL OCCULT TESTING): Global Opportunity Analysis and Industry Forecast, 2023-2032

A04470

Pages: NA

Charts: NA

Tables: NA

 Key Market Segments

  • By PRODUCT
    • GUAIAC FECAL OCCULT BLOOD (FOB) STOOL TEST
    • IMMUNO-FECAL OCCULT BLOOD (FOB) AGGLUTINATION TEST
    • LATERAL FLOW IMMUNO-FECAL OCCULT BLOOD (FOB) TEST
    • IMMUNO-FECAL OCCULT BLOOD (FOB) ELISA TEST
  • By END USER
    • HAND-HANDLED FECAL OCCULT TESTING
    • TROLLEY MOUNTED FECAL OCCULT TESTING
    • HEADBAND FECAL OCCULT TESTING

 
Key Market Players

  • bioMérieux SA
  • Cepheid
  • Roche Diagnostics Corporation
  • Siemens Healthineers
  • Beckton Dickinson and Company
  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Genesis Diagnostics
  • Hologic, Inc.
  • Alere, Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: U.S. FECAL OCCULT TESTING MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. GUAIAC FECAL OCCULT BLOOD (FOB) STOOL TEST

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. IMMUNO-FECAL OCCULT BLOOD (FOB) AGGLUTINATION TEST

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. LATERAL FLOW IMMUNO-FECAL OCCULT BLOOD (FOB) TEST

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. IMMUNO-FECAL OCCULT BLOOD (FOB) ELISA TEST

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: U.S. FECAL OCCULT TESTING MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. HAND-HANDLED FECAL OCCULT TESTING

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. TROLLEY MOUNTED FECAL OCCULT TESTING

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. HEADBAND FECAL OCCULT TESTING

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: U.S. FECAL OCCULT TESTING MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S.

        • 6.2.5.1 Market size and forecast, product

        • 6.2.5.2 Market size and forecast, end user

      • 6.2.6. Canada

        • 6.2.6.1 Market size and forecast, product

        • 6.2.6.2 Market size and forecast, end user

      • 6.2.7. Mexico

        • 6.2.7.1 Market size and forecast, product

        • 6.2.7.2 Market size and forecast, end user

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France

        • 6.3.5.1 Market size and forecast, product

        • 6.3.5.2 Market size and forecast, end user

      • 6.3.6. Germany

        • 6.3.6.1 Market size and forecast, product

        • 6.3.6.2 Market size and forecast, end user

      • 6.3.7. Italy

        • 6.3.7.1 Market size and forecast, product

        • 6.3.7.2 Market size and forecast, end user

      • 6.3.8. Spain

        • 6.3.8.1 Market size and forecast, product

        • 6.3.8.2 Market size and forecast, end user

      • 6.3.9. UK

        • 6.3.9.1 Market size and forecast, product

        • 6.3.9.2 Market size and forecast, end user

      • 6.3.10. Russia

        • 6.3.10.1 Market size and forecast, product

        • 6.3.10.2 Market size and forecast, end user

      • 6.3.11. Rest Of Europe

        • 6.3.11.1 Market size and forecast, product

        • 6.3.11.2 Market size and forecast, end user

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China

        • 6.4.5.1 Market size and forecast, product

        • 6.4.5.2 Market size and forecast, end user

      • 6.4.6. Japan

        • 6.4.6.1 Market size and forecast, product

        • 6.4.6.2 Market size and forecast, end user

      • 6.4.7. India

        • 6.4.7.1 Market size and forecast, product

        • 6.4.7.2 Market size and forecast, end user

      • 6.4.8. South Korea

        • 6.4.8.1 Market size and forecast, product

        • 6.4.8.2 Market size and forecast, end user

      • 6.4.9. Australia

        • 6.4.9.1 Market size and forecast, product

        • 6.4.9.2 Market size and forecast, end user

      • 6.4.10. Thailand

        • 6.4.10.1 Market size and forecast, product

        • 6.4.10.2 Market size and forecast, end user

      • 6.4.11. Malaysia

        • 6.4.11.1 Market size and forecast, product

        • 6.4.11.2 Market size and forecast, end user

      • 6.4.12. Indonesia

        • 6.4.12.1 Market size and forecast, product

        • 6.4.12.2 Market size and forecast, end user

      • 6.4.13. Rest of Asia Pacific

        • 6.4.13.1 Market size and forecast, product

        • 6.4.13.2 Market size and forecast, end user

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil

        • 6.5.5.1 Market size and forecast, product

        • 6.5.5.2 Market size and forecast, end user

      • 6.5.6. South Africa

        • 6.5.6.1 Market size and forecast, product

        • 6.5.6.2 Market size and forecast, end user

      • 6.5.7. Saudi Arabia

        • 6.5.7.1 Market size and forecast, product

        • 6.5.7.2 Market size and forecast, end user

      • 6.5.8. UAE

        • 6.5.8.1 Market size and forecast, product

        • 6.5.8.2 Market size and forecast, end user

      • 6.5.9. Argentina

        • 6.5.9.1 Market size and forecast, product

        • 6.5.9.2 Market size and forecast, end user

      • 6.5.10. Rest of LAMEA

        • 6.5.10.1 Market size and forecast, product

        • 6.5.10.2 Market size and forecast, end user

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Siemens Healthineers

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Beckman Coulter, Inc.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Hologic, Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. BioMérieux SA

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Beckton Dickinson And Company

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Cepheid

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Roche Diagnostics Corporation

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Abbott Laboratories

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Genesis Diagnostics

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Alere, Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL U.S. FECAL OCCULT TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. U.S. FECAL OCCULT TESTING MARKET FOR GUAIAC FECAL OCCULT BLOOD (FOB) STOOL TEST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. U.S. FECAL OCCULT TESTING MARKET FOR IMMUNO-FECAL OCCULT BLOOD (FOB) AGGLUTINATION TEST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. U.S. FECAL OCCULT TESTING MARKET FOR LATERAL FLOW IMMUNO-FECAL OCCULT BLOOD (FOB) TEST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. U.S. FECAL OCCULT TESTING MARKET FOR IMMUNO-FECAL OCCULT BLOOD (FOB) ELISA TEST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL U.S. FECAL OCCULT TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 7. U.S. FECAL OCCULT TESTING MARKET FOR HAND-HANDLED FECAL OCCULT TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. U.S. FECAL OCCULT TESTING MARKET FOR TROLLEY MOUNTED FECAL OCCULT TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. U.S. FECAL OCCULT TESTING MARKET FOR HEADBAND FECAL OCCULT TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. U.S. FECAL OCCULT TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA U.S. FECAL OCCULT TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 14. U.S. U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 15. U.S. U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. CANADA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 17. CANADA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE U.S. FECAL OCCULT TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. FRANCE U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. ITALY U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 28. ITALY U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. SPAIN U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. UK U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 32. UK U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. RUSSIA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. RUSSIA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. REST OF EUROPE U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC U.S. FECAL OCCULT TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 40. CHINA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 41. CHINA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 43. JAPAN U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. INDIA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 45. INDIA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. AUSTRALIA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. THAILAND U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 51. THAILAND U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. MALAYSIA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 53. MALAYSIA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. INDONESIA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 55. INDONESIA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA U.S. FECAL OCCULT TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 61. BRAZIL U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 62. BRAZIL U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH AFRICA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH AFRICA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 66. SAUDI ARABIA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. UAE U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 68. UAE U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. ARGENTINA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 70. ARGENTINA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. REST OF LAMEA U.S. FECAL OCCULT TESTING, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 72. REST OF LAMEA U.S. FECAL OCCULT TESTING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. SIEMENS HEALTHINEERS: KEY EXECUTIVES
  • TABLE 74. SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
  • TABLE 75. SIEMENS HEALTHINEERS: OPERATING SEGMENTS
  • TABLE 76. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
  • TABLE 77. SIEMENS HEALTHINEERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. BECKMAN COULTER, INC.: KEY EXECUTIVES
  • TABLE 79. BECKMAN COULTER, INC.: COMPANY SNAPSHOT
  • TABLE 80. BECKMAN COULTER, INC.: OPERATING SEGMENTS
  • TABLE 81. BECKMAN COULTER, INC.: PRODUCT PORTFOLIO
  • TABLE 82. BECKMAN COULTER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. HOLOGIC, INC.: KEY EXECUTIVES
  • TABLE 84. HOLOGIC, INC.: COMPANY SNAPSHOT
  • TABLE 85. HOLOGIC, INC.: OPERATING SEGMENTS
  • TABLE 86. HOLOGIC, INC.: PRODUCT PORTFOLIO
  • TABLE 87. HOLOGIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88. BIOMéRIEUX SA: KEY EXECUTIVES
  • TABLE 89. BIOMéRIEUX SA: COMPANY SNAPSHOT
  • TABLE 90. BIOMéRIEUX SA: OPERATING SEGMENTS
  • TABLE 91. BIOMéRIEUX SA: PRODUCT PORTFOLIO
  • TABLE 92. BIOMéRIEUX SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93. BECKTON DICKINSON AND COMPANY: KEY EXECUTIVES
  • TABLE 94. BECKTON DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 95. BECKTON DICKINSON AND COMPANY: OPERATING SEGMENTS
  • TABLE 96. BECKTON DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 97. BECKTON DICKINSON AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 98. CEPHEID: KEY EXECUTIVES
  • TABLE 99. CEPHEID: COMPANY SNAPSHOT
  • TABLE 100. CEPHEID: OPERATING SEGMENTS
  • TABLE 101. CEPHEID: PRODUCT PORTFOLIO
  • TABLE 102. CEPHEID: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 103. ROCHE DIAGNOSTICS CORPORATION: KEY EXECUTIVES
  • TABLE 104. ROCHE DIAGNOSTICS CORPORATION: COMPANY SNAPSHOT
  • TABLE 105. ROCHE DIAGNOSTICS CORPORATION: OPERATING SEGMENTS
  • TABLE 106. ROCHE DIAGNOSTICS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 107. ROCHE DIAGNOSTICS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 109. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 110. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 111. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 112. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. GENESIS DIAGNOSTICS: KEY EXECUTIVES
  • TABLE 114. GENESIS DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 115. GENESIS DIAGNOSTICS: OPERATING SEGMENTS
  • TABLE 116. GENESIS DIAGNOSTICS: PRODUCT PORTFOLIO
  • TABLE 117. GENESIS DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. ALERE, INC.: KEY EXECUTIVES
  • TABLE 119. ALERE, INC.: COMPANY SNAPSHOT
  • TABLE 120. ALERE, INC.: OPERATING SEGMENTS
  • TABLE 121. ALERE, INC.: PRODUCT PORTFOLIO
  • TABLE 122. ALERE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL U.S. FECAL OCCULT TESTING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL U.S. FECAL OCCULT TESTING MARKET
  • FIGURE 3. SEGMENTATION U.S. FECAL OCCULT TESTING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN U.S. FECAL OCCULT TESTING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALU.S. FECAL OCCULT TESTING MARKET
  • FIGURE 11. U.S. FECAL OCCULT TESTING MARKET SEGMENTATION, BY PRODUCT
  • FIGURE 12. U.S. FECAL OCCULT TESTING MARKET FOR GUAIAC FECAL OCCULT BLOOD (FOB) STOOL TEST, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. U.S. FECAL OCCULT TESTING MARKET FOR IMMUNO-FECAL OCCULT BLOOD (FOB) AGGLUTINATION TEST, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. U.S. FECAL OCCULT TESTING MARKET FOR LATERAL FLOW IMMUNO-FECAL OCCULT BLOOD (FOB) TEST, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. U.S. FECAL OCCULT TESTING MARKET FOR IMMUNO-FECAL OCCULT BLOOD (FOB) ELISA TEST, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. U.S. FECAL OCCULT TESTING MARKET SEGMENTATION, BY END USER
  • FIGURE 17. U.S. FECAL OCCULT TESTING MARKET FOR HAND-HANDLED FECAL OCCULT TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. U.S. FECAL OCCULT TESTING MARKET FOR TROLLEY MOUNTED FECAL OCCULT TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. U.S. FECAL OCCULT TESTING MARKET FOR HEADBAND FECAL OCCULT TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: U.S. FECAL OCCULT TESTING MARKET
  • FIGURE 26. TOP PLAYER POSITIONING,2022
  • FIGURE 27. SIEMENS HEALTHINEERS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 28. SIEMENS HEALTHINEERS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 29. SIEMENS HEALTHINEERS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 30. BECKMAN COULTER, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. BECKMAN COULTER, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. BECKMAN COULTER, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. HOLOGIC, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. HOLOGIC, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. HOLOGIC, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. BIOMéRIEUX SA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. BIOMéRIEUX SA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. BIOMéRIEUX SA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. BECKTON DICKINSON AND COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. BECKTON DICKINSON AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. BECKTON DICKINSON AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. CEPHEID: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. CEPHEID: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. CEPHEID: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. ROCHE DIAGNOSTICS CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. ROCHE DIAGNOSTICS CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. ROCHE DIAGNOSTICS CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. GENESIS DIAGNOSTICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. GENESIS DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. GENESIS DIAGNOSTICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. ALERE, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. ALERE, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. ALERE, INC.: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
U.S. Fecal Occult Testing Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved